Antibody–drug conjugates
18 articles
Roche and Hansoh sign a second, much larger ADC collaboration
- Roche and China's Hansoh signed a collaboration on a portfolio of early-stage antibody-drug conjugates, its second ADC deal after a 2025 CDH17 ADC license.
- Reports put the upfront at about $400 million plus a further $110 million after a year, with total potential payments above $15 billion and royalties.
- Hansoh leads early development through global phase 1a, after which Roche takes over development outside Greater China.
The structure is the story: a platform-style deal where the licensor runs the work through phase 1a looks like Roche buying options on China's early ADC output rather than a single asset. A headline above $15 billion is mostly back-end milestones, so the real signal is a near-$500 million near-term cash commitment. It also keeps Roche in the race with Merck, Pfizer and AstraZeneca for Chinese ADC supply.
Licensing galore: Roche ties up with Hansoh on ADCs as Rani rounds out week with Chugai pact ↗
Genmab's Rina-S posts durable phase 2 responses in platinum-resistant ovarian cancer
- Genmab reported phase 2 RAINFOL-01 data for the ADC rinatabart sesutecan (Rina-S): a 45.9% confirmed response rate in 109 heavily pretreated patients.
- Median progression-free survival was 9.5 months; TD Cowen analysts called that clearly better than the 5.6 months cited for AbbVie's Elahere.
- Activity was reported regardless of prior Elahere treatment and in patients with low or no FRα expression.
Cross-trial comparisons flatter whoever runs the later study, so I'd discount the 'clearly superior' framing. Still, activity in low-FRα and post-Elahere patients is the more interesting claim: it widens the addressable population beyond Elahere's high-expressor label. It also supports the case for the ProfoundBio buy.
Genmab's latest phase 2 data spur claim ADC is 'clearly superior' to AbbVie's Elahere ↗
Summit, AstraZeneca and Daiichi Sankyo to test ivonescimab plus Datroway, starting with Phase III in 1L TNBC
- Summit, AstraZeneca and Daiichi Sankyo announced a clinical collaboration combining ivonescimab (PD-1xVEGF bispecific) with Datroway (datopotamab deruxtecan, a TROP2-directed ADC).
- It starts with a Phase III study in first-line triple-negative breast cancer, with plans to expand to other settings including lung cancer.
- The companies will share trial costs, and each retains development and commercial rights to its own drug.
Three companies, two assets, and no one gives up rights: this is a cost-sharing structure, not a licensing deal. For Summit, pairing ivonescimab with a validated TROP2 ADC borrows AstraZeneca and Daiichi's TNBC credibility and trial muscle. For the big partners, it is a cheap hedge on the PD-1xVEGF class. I would want to see the control arm and endpoints before judging how much it de-risks.
Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestone ↗
AstraZeneca Takes a $2B Stake in Summit to Pair Ivonescimab with Its ADCs
- AstraZeneca is buying $2B of convertible preferred stock, giving it about 12% of Summit's common stock (about 10.6% fully diluted).
- The first combination pairs Summit's PD-1xVEGF bispecific ivonescimab with AstraZeneca's CLDN18.2-directed ADC in gastrointestinal cancers; a memorandum of understanding covers a broader program with more AstraZeneca ADCs.
This is AstraZeneca buying a seat rather than a pipeline: equity plus combination rights instead of an acquisition or license, keeping it close to a PD-1xVEGF class it doesn't own without paying for the asset outright. The bet is that ADC plus PD-1xVEGF combinations become a next oncology backbone, with AstraZeneca's ADC portfolio as the partner of choice. The broader MOU is non-binding, so definitive terms are the thing to watch.
AstraZeneca scales Summit's PD-1xVEGF strategy with $2B investment to fuel ADC combinations ↗
Reworking the DHIle Residue of α-Amanitin Yields Picomolar Trastuzumab–Amatoxin ADCs
- The team probed the δ-position of the 4,5-dihydroxyisoleucine residue in α-amanitin, a residue long assumed to drive RNA polymerase II inhibition.
- Two δ-modified analogs carry handles for direct linker attachment, so conjugation no longer has to go through other positions on the bicyclic peptide.
- Both were converted into trastuzumab conjugates that showed extremely high cytotoxicity on target-expressing cells, supporting these amatoxins as ADC payloads.
This is the kind of payload SAR I want more of. Amanitin's DHIle has been treated as untouchable, so finding a δ-position that tolerates substitution and doubles as a conjugation handle opens a cleaner attachment strategy than the usual lysine or Asn shuffles. I'd want to see plasma stability and bystander behaviour next, since transcription-arrest payloads live or die on therapeutic index.
Merck, Daiichi Sankyo Withdraw FDA Application for Ifinatamab Deruxtecan in Lung Cancer
- Merck & Co. and Daiichi Sankyo voluntarily withdrew their FDA BLA for ifinatamab deruxtecan, a B7-H3-targeted ADC, in previously treated ES-SCLC.
- FDA feedback indicated Phase 2 data didn't support accelerated approval, marking the alliance's second pullback for the drug after an earlier lung-toxicity-related clinical hold.
- The companies continue the Phase 3 IDeate-Lung02 confirmatory trial and other Phase 3 studies in prostate and esophageal cancer.
A second stumble for the same molecule is a real signal, but it's about ifinatamab deruxtecan's timeline, not the Merck-Daiichi deal's overall health — this alliance is bigger than one BLA. Withdrawing rather than fighting for a contested approval is the disciplined move, protecting IDeate-Lung02's confirmatory data package. But every added year gives rival B7-H3 ADC programs room to catch up.
Merck, Daiichi scrap FDA application for B7-H3 ADC in lung cancer ↗
GSK Doubles Down on China-Sourced ADCs After Hansoh Deal Delivers Phase 3 Win
- In 2023, GSK paid about $270 million upfront for ex-China rights to two Hansoh Pharma antibody-drug conjugates targeting B7-H3 and B7-H4.
- The B7-H3 candidate has since posted an 18.5-month median overall-survival benefit in relapsed small-cell lung cancer, plus a progression-free-survival win in osteosarcoma.
- GSK plans to push the B7-H4 asset into five additional Phase 3 trials, reinforcing a dual in-house/China-sourced oncology pipeline strategy.
The $270M upfront now looks like a steal — a Phase 3 survival win in SCLC plus a PFS hit in osteosarcoma would command a far richer price today, which is exactly why AstraZeneca, Merck and Pfizer scrambled to strike their own China ADC deals. Five more B7-H4 Phase 3s isn't optionality — it's GSK committing real capital to a China-sourced pipeline, not hedging it.
GSK aiming to 'balance West and East' after Hansoh deal success showed China's potential ↗
GSK licenses HUTCHMED's first-in-class KRAS-EGFR conjugate HMPL-A830 in deal worth up to $1.3B
- HUTCHMED and a GSK subsidiary signed an exclusive development and license agreement for HMPL-A830, described as a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (ATTC).
- HMPL-A830 pairs a highly selective, potent small-molecule KRAS inhibitor payload with an anti-EGFR antibody, delivering the inhibitor selectively to EGFR-expressing tumor cells while also blocking EGFR signaling.
- GSK gains worldwide development and commercialization rights excluding Mainland China, Hong Kong, Macau and Taiwan, which HUTCHMED retains.
- Deal terms: $110 million upfront, up to $1.295 billion in additional development, regulatory and commercial milestone payments, plus tiered royalties on net sales.
- HUTCHMED will conduct the global Phase 1 program, expected to start in H2 2026, after which GSK takes over subsequent clinical development and commercialization.
- Initial clinical development will focus on colorectal, pancreatic and lung cancers.
Another Western major fills its oncology pipeline via China-origination rather than in-house discovery — GSK joins a fast-growing queue of ADC/conjugate deals mining HUTCHMED's pipeline for de-risked-but-early assets. The math is telling: $110M upfront against a $1.295B ceiling is roughly 8.5% at signing — real conviction, heavily hedged, standard for a preclinical/Phase 1 asset where GSK is paying mostly for optionality until clinical data lands. The ATTC design — a small-molecule KRAS payload riding an EGFR antibody — is a genuinely differentiated angle in an overcrowded KRAS field, avoiding classic cytotoxic-ADC toxicity while adding tumor-selective targeting. And HUTCHMED keeping Greater China rights again signals its now-familiar playbook: license out ex-China, retain commercial control at home.
GSK to license Hutchmed's KRAS-EGFR cancer drug for $110M upfront ↗
Iron(II)-Activatable Conjugates Enable Tumor-Conditional Release of the HDAC Inhibitor Panobinostat
- Hydroxamic acid-based HDAC inhibitors are limited by poor selectivity among metalloenzymes and by genotoxicity risk linked to isocyanate metabolites.
- The study applies a previously reported iron(II)-activatable conjugate platform to cage the pan-HDAC inhibitor panobinostat, aiming for tumor-conditional payload release.
- In multiple myeloma cell line models, the conjugate successfully caged HDAC inhibitory activity, and a bioisosteric control conjugate showed reduced genotoxicity relative to the free hydroxamate.
- Follow-up investigation identified the carboxylesterase CES1 as responsible for unexpected proteolytic instability of the panobinostat conjugate observed both in vitro and in vivo.
- The finding is noted as a focus for future work toward mitigating hydroxamate-associated toxicity and mutagenicity through more robust tumor-conditional activation.
Caging panobinostat's hydroxamate behind an Fe(II) trigger is a sensible fix for the isocyanate-genotoxicity liability that's dogged this chemotype, and the bioisosteric control actually showing lower genotoxicity than free drug is the kind of data I'd want before calling any HDACi "safer." But what grabs me is the CES1 finding: an esterase chewing through the conjugate in vitro and in vivo is the failure mode a clean MM cell assay never warns you about. That's not a footnote — it's the design problem for the next iteration, whether you engineer around the CES1 recognition motif or add orthogonal masking. I'd rather see this reported now than discovered in an IND package; it's a useful cautionary data point for anyone building Fe(II)-activatable payloads beyond this one hydroxamate.
Bristol Myers Squibb Discontinues Orum-Partnered AML Drug ORM-6151 After Phase 1 Review
- Bristol Myers Squibb (BMS) has discontinued ORM-6151, an investigational degrader-antibody conjugate (DAC) licensed from Orum Therapeutics, after reviewing Phase 1 clinical data.
- ORM-6151 pairs an anti-CD33 antibody with a GSPT1 molecular-glue degrader payload, built on Orum's TPD² (targeted protein degradation + targeted delivery) platform; DACs are a newer conjugate class that deliver a protein-degrading payload rather than the cytotoxins used in classic antibody-drug conjugates (ADCs).
- The drug was in a Phase 1 trial for acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
- BMS licensed ORM-6151 from Orum in 2023 for a $100 million upfront payment.
- BMS notified Orum of the discontinuation on September 16, 2026, ending its obligation for up to $80 million in further milestone payments; Orum keeps the $100 million upfront already received.
The read here isn't that DACs are dead — GSPT1 degrader payloads carry known hematologic toxicity liabilities independent of the antibody delivery mechanism, so this looks more like a target/payload combination failing than an indictment of Orum's TPD² platform. Still, ORM-6151 was the most advanced, highest-profile DAC sitting inside Big Pharma hands, so its exit tightens scrutiny on the whole conjugate-degrader class before any asset reaches pivotal trials. The deal math is the sharper lesson: Orum banked its full $100M upfront and forfeits nothing, while BMS ate the Phase 1 spend and walks from up to $80M in milestones — a familiar structure where biotechs get paid for optionality, not outcomes. For Orum, losing its marquee partnered program right as it needs to prove platform durability to future licensees is the real overhang.
Bristol Myers scraps Orum-partnered cancer drug after reviewing Phase 1 data ↗
NHS England to Fund AstraZeneca's Enhertu After UK-US Pricing Deal
- NICE, which sets drug-funding recommendations for NHS England, will fund Enhertu (trastuzumab deruxtecan) for HER2-low metastatic or unresectable breast cancer after chemotherapy, reversing a July 2024 rejection on cost grounds.
- The reversal follows a UK-US pharmaceutical pricing deal that led NICE to raise its cost-effectiveness threshold and revise its appraisal methodology, making some costlier innovative drugs newly reimbursable.
- Enhertu, an antibody-drug conjugate co-developed by AstraZeneca and Daiichi Sankyo, has been reported in studies to meaningfully extend survival for this patient group versus chemotherapy alone, though the size of the benefit varies.
- An estimated 1,000 patients in England are expected to gain access, with treatment available within days of the decision.
NICE just permanently loosened its willingness-to-pay bar — as a negotiated line item in a bilateral trade deal, not a one-off cost-effectiveness review. That's the story here, not the roughly 1,000 patients gaining access: expect other governments squeezed between fiscal discipline and access pressure, and other pharma negotiators facing NICE, to point to this precedent. For AstraZeneca and Daiichi Sankyo, it de-risks Enhertu's ex-US rollout playbook: reimbursement fights in other cost-constrained markets (Canada, Australia, parts of Europe) just got a stronger comparator to cite. More broadly, this nudges the ceiling on what NICE will pay for high-cost ADCs and next-gen oncology assets generally, benefiting the wider oncology ADC pipeline queuing up for UK launch, not just this one drug. Watch whether AZ/Daiichi price other Enhertu indications, or future ADCs, against this new threshold.
England to cover AstraZeneca breast cancer drug, a result of U.K.-U.S. drug pricing deal ↗
Antibody-Guided PROTAC Conjugate Blocks Tumor-Stroma Crosstalk by Silencing Extracellular Vesicles
- Researchers built Ctx-ETAC, a degrader-antibody conjugate pairing the approved EGFR antibody cetuximab with an engineered PROTAC payload, attached via a bioorthogonal reaction at a defined, controlled ratio per antibody.
- Its PROTAC payload pairs an indomethacin-derived COX-2 ligand with a VHL-recruiting peptide via a cathepsin B-cleavable linker, releasing the degrader selectively inside EGFR-positive tumor cells and activated fibroblasts.
- Degrading COX-2 in both cell types substantially curtails extracellular vesicle secretion, severing a key tumor-stroma signaling channel and nudging fibroblasts toward a quiescent, less tumor-supportive state.
- In a lung cancer xenograft model, Ctx-ETAC outperformed cetuximab alone in restraining tumor growth without added systemic toxicity, supporting microenvironment-targeted degradation as a therapeutic strategy.
Finally, a DAC that isn't just "ADC with a cooler payload" — swapping a cytotoxin for a VHL-PROTAC means efficacy doesn't hinge on brute-force poisoning of every internalized antibody; you get catalytic, event-driven target destruction instead. Smart target choice: COX-2 isn't the oncogenic driver, it's stromal plumbing. Cutting EV secretion to defuse tumor-fibroblast crosstalk instead of chasing EGFR resistance mutations directly is a genuinely different SAR logic than the usual "degrade the driver" playbook. Chemistry-wise, nothing exotic — indomethacin-COX-2 ligand, VHL peptide, cathepsin B-cleavable linker, defined-DAR bioorthogonal attachment. That's the point: boringly tractable, which is exactly what a translatable conjugation platform should look like. Real question is whether COX-2/EV silencing holds up in a fibroblast-rich, resistant tumor, not just a clean xenograft — but as a proof that microenvironment-directed degradation is maturing past a concept, this is convincing.
NHS England to Reimburse AstraZeneca's Enhertu for HER2-Low Breast Cancer After US-UK Pricing Deal
- Enhertu (trastuzumab deruxtecan), an AstraZeneca/Daiichi Sankyo HER2-targeting antibody-drug conjugate, will now be reimbursed by NHS England for HER2-low metastatic breast cancer.
- The move reverses NICE's July 2024 rejection of the drug for this indication, ending a years-long access dispute.
- It follows a new NICE agreement made possible by a broader U.S.-U.K. drug pricing deal (announced December 2025), which raised NICE's cost-effectiveness thresholds from about £20,000-£30,000 to £25,000-£35,000 per quality-adjusted life year.
- A new quality-of-life assessment methodology, published August 27, 2026, also supported the reassessment.
- About 1,000 women a year in England with HER2-low metastatic breast cancer are expected to now qualify, with studies reporting an average survival gain of roughly six months.
The science and data here are unchanged from NICE's 2024 rejection — this is a payer-economics win, not a clinical one, and it's easy to conflate the two. What actually moved was NICE's cost-effectiveness ceiling, from roughly £20-30K to £25-35K per QALY, engineered by the broader US-UK pricing deal, not new trial results. That's the real story: the first tangible commercial outcome traceable to that trade agreement, and it hands every company with a NICE-rejected asset a concrete playbook for reopening the case. Commercially, ~1,000 patients/year in England is a rounding error for AZ/Daiichi's global Enhertu franchise — the payoff is precedent, not revenue. Watch for ripple effects: rival ADCs and other HER2-low contenders now face a materially easier cost-effectiveness bar, reshaping competitive dynamics in an increasingly crowded ADC pipeline.
England to cover AstraZeneca breast cancer drug, a result of U.K.-U.S. drug pricing deal ↗
Bifunctional Pyridine Linker Enables Sequential, Stable Bioconjugation for ADCs and Peptides
- A programmable, bifunctional pyridine scaffold bearing a thianthrenium leaving group and a fluorine handle enables two sequential, chemoselective coupling reactions — first with alkylamines, then with cysteine thiols.
- The resulting aryl-cysteine linkage is non-chiral and stable, addressing limitations of existing bioconjugation approaches that often yield reversible linkages or stereochemical mixtures.
- Both coupling steps show high functional-group tolerance and chemoselectivity, making the chemistry compatible with complex peptides and proteins.
- The platform was applied to late-stage peptide diversification and stapling, as well as site-selective protein functionalization.
- Researchers also used the method to build an analog of the HER2-targeting antibody-drug conjugate MRG002 with a tunable drug-to-antibody ratio, reporting improved payload retention in serum relative to conventional linkage chemistry.
Maleimide-cysteine chemistry's dirty secret is retro-Michael instability — payload leaches back into circulation, and DAR isn't as fixed as the spec sheet claims. This bifunctional pyridine/thianthrenium scaffold attacks that head-on: the resulting aryl-thioether is non-chiral and hydrolytically stable, so no diastereomer mixtures and no slow linker exchange with serum thiols. Sequential chemoselectivity — amine coupling first, cysteine second, off one handle — is a real practical upgrade for installing orthogonal payloads/tags, not just another NHS-ester variant. What earns my attention is that they didn't stop at peptide-stapling demos: a tunable-DAR HER2 ADC analog of MRG002 with improved serum payload retention versus conventional linkage is the kind of proof point that actually moves a methodology from academic curiosity toward something worth piloting. Thianthrenium reagent scale-up and cost will decide if it ever displaces maleimide on a GMP line.
New Homocamptothecin Payload Simplifies ADC Drug Design
- Camptothecin-class payloads such as DXd currently dominate antibody-drug conjugate (ADC) design, powering approved drugs in the Enhertu family.
- Researchers created a new homocamptothecin analog, H2, built around a simplified seven-membered-ring (hydroxybutyl) core that avoids the lengthy, multi-step F-ring synthesis required for DXd-type payloads.
- H2 retained potent intrinsic cytotoxicity while showing markedly better resistance to hydrolytic breakdown than earlier homocamptothecin designs.
- Trastuzumab-based ADC candidates carrying H2 produced strong bystander-killing effects and antiproliferative activity in vitro, mirroring T-DXd.
- In a HER2-positive xenograft tumor model, the H2-based conjugates matched the antitumor efficacy of the benchmark payload T-DXd.
- The results position the simplified homocamptothecin scaffold as a promising, more synthetically accessible class of next-generation ADC payloads.
• Mechanistically nothing new — H2 is still a topo-I poison in the DXd lineage, so this is a manufacturing/route paper more than a pharmacology one, and that's fine by me. • The real value is ditching the multi-step F-ring synthesis: a payload that matches DXd's potency but scales more cleanly wins on cost-of-goods and batch consistency, which matter as much as IC50 once you're past discovery. • Better hydrolytic stability is the number I'd chase — payload/linker instability in circulation usually hurts therapeutic index more than intrinsic potency does. • "Matched T-DXd" in one xenograft tells you efficacy is in the ballpark, not that PK, tolerability, or TI are equivalent — I want linker compatibility data (cleavable vs. non-cleavable), DAR optimization, and real in vivo tox before calling this a DXd alternative. • Good to see payload diversification beyond DXd/MMAE regardless — worth banking as backup chemistry even pre-clinic.
Homocamptothecin Payloads with Enhanced Potency for Antibody-Drug Conjugates ↗
TwoStep Therapeutics Lands $62.5M and FDA IND Clearance for Peptide-Based ADC Alternative
- TwoStep Therapeutics, a 2024 Stanford spinout, announced an oversubscribed $62.5M Series A financing on September 10, 2026, alongside FDA clearance of the investigational new drug (IND) application for its lead candidate, TS-104.
- The round was led by Insight Partners and Medical Excellence Capital, with pharma-linked corporate venture arms M Ventures (Merck KGaA) and Pfizer Ventures co-leading; existing investors NFX, 2048 Ventures, and Stanford University also participated, bringing total funding raised to $71.2M.
- TS-104 is a first-in-class multi-specific peptide-drug conjugate (PDC) that pairs a polyspecific integrin-binding peptide, engineered to bind five tumor-associated integrins across solid tumors, with the cytotoxic payload MMAE, also used in several approved antibody-drug conjugates.
- The company positions this peptide-based platform as an alternative to antibody-based ADCs for reaching solid tumor targets.
- The IND clearance opens the way for a first-in-human Phase 1 trial, with patient enrollment expected later this year.
PDCs are pitching themselves as the cheaper, more tumor-penetrant cousin of ADCs — same MMAE payload, smaller delivery vehicle, potentially better access to solid-tumor stroma where antibodies struggle. That's a direct pitch at the ADC franchise now dominating oncology dealmaking. The investor list matters more than the dollar figure: M Ventures and Pfizer Ventures co-leading, not just writing a check, reads as two ADC-heavy pharmas hedging their own franchises and buying an early look at a modality that could either complement or cannibalize their antibody platforms. Oversubscribed Series A plus IND clearance inside two years of founding is a fast validation cycle for a still-unproven conjugate class — worth watching whether Phase 1 tolerability holds up before any partnering thesis gets real.
Exclusive: Cancer biotech TwoStep gets $62.5M to take twist on ADCs into clinic ↗
New Conjugate Chemistry Releases Payload on Target Binding, Bypassing Endocytosis
- Researchers introduce a binding-to-release (BTR) strategy that triggers drug-conjugate payload release directly upon target binding, rather than requiring receptor-mediated endocytosis.
- The approach uses a new bioconjugation reaction, phosphorus(V)-phenol exchange (PhoPEx) — inspired by SuFEx click chemistry — engineered so that chemistry within the binding pocket itself cleaves the drug free once the conjugate engages its target.
- Because only a minority of drug targets support efficient endocytosis, this binding-triggered release could extend conjugate-based therapies to otherwise poorly internalizing targets.
- The authors describe proof-of-concept work with a conjugate targeting fibroblast activation protein (FAP), evaluated from in vitro settings through patient-derived tissue specimens.
The clever bit is topological: you need a nucleophilic residue (Ser/Tyr/Lys) sitting close enough to the P(V) center once the conjugate is bound, so this only works when pocket geometry cooperates — not a universal fix, more a case-by-case design problem per target. SuFEx proved robust and bioorthogonal enough to become a real click-chemistry platform; whether PhoPEx's release kinetics and selectivity hold up outside FAP is the real open question — proof-of-concept in patient tissue is promising but still one target. What I like: it decouples release from endocytosis and lysosomal processing entirely, which is the actual bottleneck for most ADC-style approaches against non-internalizing or slowly-trafficking surface receptors (GPCRs, some ion channels, stromal markers like FAP itself). If the chemistry generalizes, it's a genuine expansion of addressable target space for conjugates, not just a linker tweak.
A binding-to-release strategy for targeted anticancer drug delivery ↗
Genentech Licenses DualityBio's Next-Gen ADC Payload Platform to Counter TOPO1 Resistance
- Genentech has licensed DualityBio's DUPAC antibody-drug-conjugate payload platform: $45M upfront, over $1B in milestones, plus tiered royalties.
- Shanghai-based DualityBio handles target-specific ADC discovery through Phase 1a on Genentech-chosen oncology targets; Genentech then owns exclusive rights through late-stage development and commercialization.
- The rationale is payload resistance — topoisomerase-1 (TOP1) inhibitor payloads underpin most current ADCs, including DualityBio's own BioNTech-partnered HER2 asset, and resistance is rising as these drugs reach earlier treatment lines.
- DUPAC is pitched as a next-gen payload that stays active in TOP1-resistant tumors.
- This follows DualityBio's 2023 BioNTech deal (>$1.5B) and extends MNC pharma's pattern of sourcing ADC payload innovation from China.
The economics: $45M upfront against $1B+ in milestones is a cheap call option for Genentech — DualityBio absorbs discovery and Phase 1a risk, and Genentech only pays once DUPAC clears its resistance hurdle. That's a smaller headline number than DualityBio's 2023 BioNTech deal, hinting at either narrower scope or softer terms on partner #2. Strategically, this is Roche/Genentech hedging against a class-wide ceiling: TOP1 payloads underpin nearly the entire current ADC generation, including Enhertu and DualityBio's own BioNTech HER2 asset, so resistance will bite everyone eventually. It also confirms Genentech won't build payload discovery in-house, joining Pfizer/Seagen and AbbVie/ImmunoGen in sourcing ADC innovation from China. For DualityBio, a second nine-figure MNC partner in three years validates the platform model — though whether DUPAC actually beats resistant tumors is still unproven.
Roche bets $1B+ on DualityBio's ADC tech to tackle TOPO1 resistance ↗